Ibrutinib: searching for a partner drug

被引：5

作者：

Kater, Arnon P. ^{[1
,2
]}

Brown, Jennifer R. ^{[3
]}

机构：

[1] Univ Amsterdam, Amsterdam UMC, Dept Hematol & Lymphoma, NL-1105 AZ Amsterdam, Netherlands

[2] Univ Amsterdam, Amsterdam UMC, Canc Ctr Amsterdam, NL-1105 AZ Amsterdam, Netherlands

[3] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA

来源：

LANCET ONCOLOGY | 2019年 / 20卷 / 01期

关键词：

VENETOCLAX; RITUXIMAB; LEUKEMIA;

D O I：

10.1016/S1470-2045(18)30861-1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：3 / 5

页数：4

共 10 条

[1]

[Anonymous], BLOOD S1

[2] Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2 [J].

Barr, Paul M. ;

Robak, Tadeusz ;

Owen, Carolyn ;

Tedeschi, Alessandra ;

Bairey, Osnat ;

Bartlett, Nancy L. ;

Burger, Jan A. ;

Hillmen, Peter ;

Coutre, Steven ;

Devereux, Stephen ;

Grosicki, Sebastian ;

McCarthy, Helen ;

Li, Jianyong ;

Simpson, David ;

Offner, Fritz ;

Moreno, Carol ;

Zhou, Cathy ;

Styles, Lori ;

James, Danelle ;

Kipps, Thomas J. ;

Ghia, Paolo .

HAEMATOLOGICA, 2018, 103 (09) :1502-1510

[3] Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia [J].

Burger, J. A. ;

Tedeschi, A. ;

Barr, P. M. ;

Robak, T. ;

Owen, C. ;

Ghia, P. ;

Bairey, O. ;

Hillmen, P. ;

Bartlett, N. L. ;

Li, J. ;

Simpson, D. ;

Grosicki, S. ;

Devereux, S. ;

McCarthy, H. ;

Coutre, S. ;

Quach, H. ;

Gaidano, G. ;

Maslyak, Z. ;

Stevens, D. A. ;

Janssens, A. ;

Offner, F. ;

Mayer, J. ;

O'Dwyer, M. ;

Hellmann, A. ;

Schuh, A. ;

Siddiqi, T. ;

Polliack, A. ;

Tam, C. S. ;

Suri, D. ;

Cheng, M. ;

Clow, F. ;

Styles, L. ;

James, D. F. ;

Kipps, T. J. ;

Keating, Michael ;

Jen, Jie ;

Jindra, Pavel ;

Simkovic, Martin ;

Braester, Andrei ;

Ruchlemer, Rosa ;

Foa, Roberto ;

Semenzato, Gianpietro ;

Hawkins, Timothy ;

Atanasio, Carolina Moreno ;

Demirkan, Fatih ;

Kaynar, Leylagul ;

Pylypenko, Halyna ;

Fox, Christopher ;

Thirman, Michael ;

Campbell, Philip .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (25) :2425-2437

[4] Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions [J].

Goede, Valentin ;

Fischer, Kirsten ;

Busch, Raymonde ;

Engelke, Anja ;

Eichhorst, Barbara ;

Wendtner, Clemens M. ;

Chagorova, Tatiana ;

de la Serna, Javier ;

Dilhuydy, Marie-Sarah ;

Illmer, Thomas ;

Opat, Stephen ;

Owen, Carolyn J. ;

Samoylova, Olga ;

Kreuzer, Karl-Anton ;

Stilgenbauer, Stephan ;

Doehner, Hartmut ;

Langerak, Anton W. ;

Ritgen, Matthias ;

Kneba, Michael ;

Asikanius, Elina ;

Humphrey, Kathryn ;

Wenger, Michael ;

Hallek, Michael .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (12) :1101-1110

[5] Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity [J].

Kohrt, Holbrook E. ;

Sagiv-Barfi, Idit ;

Rafiq, Sarwish ;

Herman, Sarah E. M. ;

Butchar, Jonathon P. ;

Cheney, Carolyn ;

Zhang, Xiaoli ;

Buggy, Joseph J. ;

Muthusamy, Natarajan ;

Levy, Ronald ;

Johnson, Amy J. ;

Byrd, John C. .

BLOOD, 2014, 123 (12) :1957-1960

[6] The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy [J].

Landau, Dan A. ;

Sun, Clare ;

Rosebrock, Daniel ;

Herman, Sarah E. M. ;

Fein, Joshua ;

Sivina, Mariela ;

Underbayev, Chingiz ;

Liu, Delong ;

Hoellenriegel, Julia ;

Ravichandran, Sarangan ;

Farooqui, Mohammed Z. H. ;

Zhang, Wandi ;

Cibulskis, Carrie ;

Zviran, Asaf ;

Neuberg, Donna S. ;

Livitz, Dimitri ;

Bozic, Ivana ;

Leshchiner, Ignaty ;

Getz, Gad ;

Burger, Jan A. ;

Wiestner, Adrian ;

Wu, Catherine J. .

NATURE COMMUNICATIONS, 2017, 8

[7] Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients [J].

Mato, A. R. ;

Hill, B. T. ;

Lamanna, N. ;

Barr, P. M. ;

Ujjani, C. S. ;

Brander, D. M. ;

Howlett, C. ;

Skarbnik, A. P. ;

Cheson, B. D. ;

Zent, C. S. ;

Pu, J. J. ;

Kiselev, P. ;

Foon, K. ;

Lenhart, J. ;

Bachow, S. Henick ;

Winter, A. M. ;

Cruz, A. -L. ;

Claxton, D. F. ;

Goy, A. ;

Daniel, C. ;

Isaac, K. ;

Kennard, K. H. ;

Timlin, C. ;

Fanning, M. ;

Gashonia, L. ;

Yacur, M. ;

Svoboda, J. ;

Schuster, S. J. ;

Nabhan, C. .

ANNALS OF ONCOLOGY, 2017, 28 (05) :1050-1056

[8] Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial [J].

Moreno, Carol ;

Greil, Richard ;

Demirkan, Fatih ;

Tedeschi, Alessandra ;

Anz, Bertrand ;

Larratt, Loree ;

Simkovic, Martin ;

Samoilova, Olga ;

Novak, Jan ;

Ben-Yehuda, Dina ;

Strugov, Vladimir ;

Gill, Devinder ;

Gribben, John G. ;

Hsu, Emily ;

Lih, Chih-Jian ;

Zhou, Cathy ;

Clow, Fong ;

James, Danelle F. ;

Styles, Lori ;

Flinn, Ian W. .

LANCET ONCOLOGY, 2019, 20 (01) :43-56

[9] Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia [J].

Seymour, J. F. ;

Kipps, T. J. ;

Eichhorst, B. ;

Hillmen, P. ;

D'Rozario, J. ;

Assouline, S. ;

Owen, C. ;

Gerecitano, J. ;

Robak, T. ;

De la Serna, J. ;

Jaeger, U. ;

Cartron, G. ;

Montillo, M. ;

Humerickhouse, R. ;

Punnoose, E. A. ;

Li, Y. ;

Boyer, M. ;

Humphrey, K. ;

Mobasher, M. ;

Kater, A. P. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (12) :1107-1120

[10] Resistance to ABT-199 induced by microenvironmental signals in chronic iymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors [J].

Thijssen, Rachel ;

Slinger, Erik ;

Weller, Katinka ;

Geest, Christian R. ;

Beaumont, Tim ;

van Oers, Marinus H. J. ;

Kater, Arnon P. ;

Eldering, Eric .

HAEMATOLOGICA, 2015, 100 (08) :E302-E306

← 1 →